Navigation Links
Severe breathing disorders during sleep are associated with an increased risk of dying
Date:8/17/2009

ndition (that is, those with AHI less than 5). Death from coronary heart disease was found to be associated with sleep-disordered breathing in men, but not in women. Those who had milder sleep-breathing disorders did not have a statistically significant increased risk of dying.

As an observational study, this research cannot determine whether sleep-disordered breathing is the actual cause of deaths, rather than a factor that happens to be associated with fatal conditions, nor whether treating sleep-disorder breathing can lengthen life. To address this question, the authors suggest "additional research in the form of randomized clinical trials to assess if treatment [of sleep-disordered breathing] can reduce premature mortality associated with this common and chronic disorder."


'/>"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
Source:Eurekalert

Page: 1 2

Related biology news :

1. Research shows rates of severe childhood obesity have tripled
2. Smaller than expected, but severe, dead zone in Gulf of Mexico
3. UF makes gene therapy advance in severe genetic disorder
4. New center at Georgia Tech aims to improve recovery of soldiers with severe injuries
5. Preclinical work shows how one gene causes severe mental retardation
6. UT Public Health researchers find link to severe Staph infections
7. Severe gestational hypertension may protect against testicular cancer
8. Franklin Square to study airway bypass procedure for severe emphysema
9. Severe climate change costs forecast for Pennsylvania, N.C., Tennessee, N.D.
10. Cortisol and fatty liver: Researchers find cause of severe metabolic disorders
11. Toxoplasmosis found more severe in Brazil compared to Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... since Aristotle have puzzled over the reasons for mass ... up to several hundred individuals drive themselves up onto ... some light on whether family relationships play a role ... healthy whales. One hypothesis regarding the reason ...
... announced a $20,000 grant from Orvis Company, Inc. that will ... along the "Path of the Pronghorn." For more ... km) migration of pronghorn along the path between wintering grounds ... Grand Teton National Park (GTNP). This led to collaboration with ...
... curiosity about patterns of growth and development in pig brains ... scientists Rod Johnson and Ryan Dilger have developed a model ... answer important questions about human brain development. "It is ... neonatal period to sexual maturity," said Johnson. "Until we ...
Cached Biology News:Oh mother, where art thou? 2Oh mother, where art thou? 3More good news for pronghorn 2Pig brain models provide insights into human cognitive development 2
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... operation up to 1500 bar. The sanitary design gauge of the NS2006L is ... , The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Successfully Delivered into the Bloodstream- Data Demonstrates ... OxycodoneMELBOURNE, Australia, May 29 Phosphagenics Limited ... the successful completion of preclinical studies related ... The results of the preclinical studies demonstrated ...
... May 29 The Gerresheimer,Group today opened ... in China.,The high-tech production facility constructed in ... in high-quality pharmaceutical,vials and cartridges for injection ... industry on both a local and international ...
... Pa., May 28 Centocor Ortho Biotech Products, L.P. ... be presented at the 45th American Society of Clinical ... 29 to June 2, 2009. The studies were ... research partner, Ortho Biotech Oncology Research and Development, a ...
Cached Biology Technology:Phosphagenics Announces Completion of Transdermal Patch Prototypes 2Phosphagenics Announces Completion of Transdermal Patch Prototypes 3Phosphagenics Announces Completion of Transdermal Patch Prototypes 4Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China 2Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China 3Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 7Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 8Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 9Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 10Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 11
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... Disposable, clear, APET plastic tray. Ideal ... identify those trays used for multipurposes. Pour ... liquid. A marker or label may be ... stacking trays on rockers or shakers for ...
ID clarifier: non-treated with lid...
... The Staccato Series of systems provide fast and reliable ... and drug development laboratories. Staccato systems are available in ... Custom Systems Series. ... All ...
Biology Products: